Table 4.
Absolute and relative risk of death from breast cancer according to mean MRPS23/tumour cell, MRPS23/CEP17 ratio and amplification status
| Mean MRPS23/tumour cell, primary tumour | MRPS23/CEP17 ratio, primary tumour | Amplification status, primary tumours | |||||
|---|---|---|---|---|---|---|---|
| < 4 | ≥ 4, < 6 | ≥ 6 | < 2 | ≥ 2 | MRPS23−a | MRPS23+b | |
| Cum. risk after 5 years (%) (95% CI) | 21 (18–24) | 24 (12–44) | 38 (21–62) | 21 (18–25) | 29 (18–46) | 21 (18–25) | 29 (18–44) |
| Cum. risk after 10 years (%) (95% CI) | 35 (31–39) | 34 (20–55) | 43 (25–66) | 30 (27–34) | 41 (30–58) | 30 (27–34) | 40 (27–56) |
| HR, unadjusted (95% CI) | 1.0 | 0.9 (0.5–1.7) | 1.5 (0.8–2.8) | 1.0 | 1.2 (0.8–2.0) | 1.0 | 1.2 (0.7–1.9) |
| HR adjusted for age (95% CI) | 1.0 | 0.9 (0.5–1.7) | 1.5 (0.8–2.8) | 1.0 | 1.3 (0.8–2.1) | 1.0 | 1.2 (0.7–1.9) |
| HR adjusted for stage (95% CI) | 1.0 | 0.8 (0.4–1.5) | 1.2 (0.6–2.4) | 1.0 | 1.2 (0.7–1.9) | 1.0 | 1.0 (0.6–1.7) |
| HR adjusted for grade (95% CI) | 1.0 | 0.7 (0.4–1.4) | 1.3 (0.7–2.4) | 1.0 | 1.1 (0.7–1.7) | 1.0 | 1.0 (0.6–1.6) |
| HR adjusted for Ki67 (95% CI) | 1.0 | 0.7 (0.4–1.4) | 1.1 (0.6–2.2) | 1.0 | 1.0 (0.6–1.6) | 1.0 | 1.0 (0.6–1.6) |
| HR adjusted for HER2 (95% CI) | 1.0 | 0.9 (0.5–1.6) | 1.2 (0.6–2.3) | 1.0 | 1.0 (0.6–1.7) | 1.0 | 1.0 (0.6–1.6) |
CI confidence interval, HR hazard ratio
aMRPS23/CEP17 < 2 and mean MRPS23 < 6
bMRPS23/CEP17 ≥ 2 and/or mean MRPS23 ≥ 6